NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Illumina, Inc. (ILMN) Stock Analysis

Illumina, Inc. (ILMN) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

ILMN

$218.22

−$3.44 (−1.55%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ILMN with… →

ILMN Key Statistics

As of Sep 4, 2026
Trading
Open
$216.74
Previous Close
$221.66
Day's Range
213.95–219.58
52-Week Range
88.00–231.81
Volume
1.74M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.47
Valuation
Market Cap
$32.95B
P/E Ratio
41.33
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
35.78
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.56
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.33
EPS (ttm)Profit attributable to each share over the last twelve months.
5.28
Financials (FY)
Revenue (FY)
$4.34B−0.66%
Net Income (FY)
$850.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
18.34%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
151.00M
1-Year Return
+123.40%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
1.93M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ILMN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+66.38%
2025−1.85%
2024−1.34%
2023−31.14%
2022−46.85%
2021+2.82%
2020+11.53%
2019+10.61%
2018+37.27%
2017+70.64%
2016 (partial year)−23.08%

As of September 4, 2026.

ILMN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.34B$850.00M19.6%
2024$4.37B−$1.22B−28.0%
2023$4.50B−$1.16B−25.8%
2022$4.58B−$4.40B−96.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.34B$2.87B$817.00M$850.00M19.6%
2024$4.37B$2.86B$600.00M−$1.22B−28.0%
2023$4.50B$2.74B−$222.00M−$1.16B−25.8%
2022$4.58B$2.97B$354.00M−$4.40B−96.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ILMN Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricILMNDiagnostics & Research medianvs median
P/E41.3333.0825% above
P/S ratio7.334.9947% above
Profit margin18.34%0.00%18.3 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Illumina, Inc. (ILMN) at $32.95B. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 8,600.

ILMN last closed at $218.22 on September 4, 2026. That is −$3.44 (−1.55%) against the previous close. Over the past 52 weeks the price has ranged from $88.00 to $231.81. The latest close sits 147.98% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $4.34B. That is −0.66% against the prior fiscal year, when revenue was $4.37B. Net income for the same year was $850.00M. Profit margin runs at 18.34%. That is 18.3 percentage points above the Diagnostics & Research median of 0%. Trailing earnings per share are 5.28.

Across the 4 fiscal years on file, revenue moves from $4.58B in 2022 to $4.34B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 41.33 times earnings. That is 24.94% above the Diagnostics & Research median of 33.08. On forward earnings the ratio is 35.78. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.56. Measured against sales, the shares trade at 7.33 times revenue. On price-to-sales that is 46.93% above the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.47. Annualized volatility over the trailing 10 years is 42.43%. Over the trailing twelve months the price has returned +123.40%. Across 10 years the annualized return works out at +2.94%.

Growth & Income

No dividend is on file for ILMN.

2026 is still running; the price is +66.38% year to date. Across the complete calendar years on file, 2017 returned +70.64% and 2022 returned −46.85%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Illumina, Inc. (ILMN) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Illumina, Inc. ILMN $32.95B 41.3
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Illumina, Inc. trades at a P/E of 41.3.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Illumina, Inc.

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Visit website →